Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here’s What’s Driving the Move
Key Takeaways:
- Jazz Pharmaceuticals (JAZZ) is a biopharmaceutical company focused on developing and commercializing products for unmet medical needs, with a market cap of around $14 billion.
- JAZZ reported Q1 2026 adjusted EPS of $6.34, significantly beating the consensus estimate of $4.57, and revenue rose 19% to $1.1 billion.
- JAZZ stock could rise from $229 to around $284 per share by December 2028, implying a 24.1% total return.
What Happened?
Jazz Pharmaceuticals plc (JAZZ) has been one of the most remarkable turnaround stories of the past 12 months. The stock rose from a 52-week low of $98 to over $229, more than doubling in a single year. Q1 2026 adjusted EPS of $6.34 crushed the consensus estimate of $4.57. Revenue climbed 19% year over year to $1.1 billion, showing the strength of the commercial portfolio.
The company is building a serious oncology franchise alongside its core sleep disorder business. The FDA accepted a supplemental biologics license application for Ziihera with priority review in April 2026. Ziihera, known generically as zanidatamab, is a HER2-targeted bispecific antibody being developed for multiple cancer types.
Separately, the European Medicines Agency recommended approval of Zepzelca combined with atezolizumab for a type of lung cancer in March 2026.
Jazz has also delivered consistency in the core sleep franchise. Xywav and Xyrem generate strong recurring cash flows from narcolepsy and idiopathic hypersomnia patients.
New CEO Renee Gala took the helm in July 2025 and has maintained momentum across both the commercial and pipeline fronts. The company’s Q4 2025 results also beat estimates, extending the track record of outperformance.
Investors are now weighing whether the stock’s dramatic re-rating has fully priced in the pipeline opportunity. The stock trades near its 52-week high, and analyst targets imply only modest additional upside.
But the Ziihera priority review and Zepzelca approval are concrete pipeline catalysts in the near term. Here’s why Jazz Pharmaceuticals stock could continue to reward investors who stay patient through 2028.
What the Model Says for JAZZ Stock
We analyzed the upside potential for Jazz Pharmaceuticals stock based on its durable sleep disorder franchise, accelerating oncology commercialization, and consistently high operating margins.
Based on estimates of 7.2% annual revenue growth, 43.4% operating margins, and a normalized P/E multiple of 9.4x, the model projects Jazz Pharmaceuticals’ stock could rise from $229 to around $284 per share.
That would be a 24.1% total return, or a 8.5% annualized return over the next 2.6 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for JAZZ stock:
1. Revenue Growth: 7.2%
Jazz Pharmaceuticals reported Q1 2026 revenue of $1.1 billion, up 19% year over year. Q4 2025 revenue of $1.2 billion grew 10% year over year and beat consensus estimates. The company has delivered strong and consistent revenue beats across multiple consecutive quarters, demonstrating real commercial momentum.
The sleep disorder franchise with Xywav generates stable and recurring revenue from a loyal patient base. Ziihera, Zepzelca, and Epidiolex represent meaningful growth opportunities in oncology and neurology. The FDA priority review for a new Ziihera combination indication is a near-term catalyst that could expand the addressable patient population substantially.
Based on analysts’ consensus estimates, we used 7.2% annual revenue growth. The forward two-year consensus revenue CAGR stands at approximately 6.3%, so our assumption is slightly above consensus to reflect pipeline upside. It is a measured growth rate that acknowledges both the core franchise durability and the incremental pipeline contribution.
2. Operating Margins: 43.4%
Jazz Pharmaceuticals operates with a 29.2% LTM EBIT margin and an exceptional 91.5% gross margin. The company’s business model is highly capital efficient, as marketed drugs carry very low incremental costs once they reach commercial scale. These are among the strongest margin characteristics in specialty pharmaceuticals globally.
The Q1 2026 adjusted EPS of $6.34 represented a massive beat versus the $4.57 estimate, reflecting the operating leverage in the business. Q4 2025 adjusted EPS of $6.64 similarly beat expectations. These consistent earnings beats confirm that the company is executing well and managing its cost structure effectively.
Based on analysts’ consensus estimates, we used 43.4% operating margins. This reflects a meaningful step up from the current 29.2% EBIT margin, driven by operating leverage as the oncology products scale. It also accounts for continued research and development spending associated with Ziihera and Zepzelca.
3. Exit P/E Multiple: 9.4x
Jazz Pharmaceuticals currently trades at a forward NTM P/E of 9.38x. This is notably low for a specialty pharma company with a 91.5% gross margin and consistent earnings beats. The compressed multiple reflects market caution about long-term pipeline durability beyond the current marketed drugs.
The 52-week low of $98 and the current price of $229 tell the story of a dramatic re-rating driven by pipeline progress and earnings momentum. The stock more than doubled in a single year. But even after this rally, the multiple remains conservative relative to the company’s margin profile.
Based on analysts’ consensus estimates, we used a 9.4x exit P/E multiple. This is consistent with the current trading multiple and assumes the market maintains its conservative posture about long-term growth. If Ziihera achieves strong commercial uptake, the multiple could expand meaningfully and create additional return upside.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for JAZZ stock through 2034 show varied outcomes based on oncology pipeline commercialization, sleep franchise durability, and regulatory outcomes (these are estimates, not guaranteed returns):
- Low Case: Pipeline momentum disappoints, and revenue growth misses targets → around 1% negative annual returns
- Mid Case: Ziihera and Zepzelca gain commercial traction alongside a stable sleep franchise → around 6% annual returns
- High Case: Pipeline execution is solid, but growth trails the mid case trajectory → around 5% annual returns
Going forward, Jazz Pharmaceuticals’ stock will depend on Ziihera’s commercialization progress and the strength of the sleep disorder franchise. The near-term model projects around 8.5% annualized returns through 2028, which may represent the better risk-adjusted window compared to the longer-term advanced scenarios.
Investors should monitor Ziihera’s priority review outcome and Zepzelca’s commercial launch as the key catalysts for the next meaningful re-rating.
See what analysts think about JAZZ stock right now (Free with TIKR) >>>
Should You Invest in Jazz Pharmaceuticals?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JAZZ, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track JAZZ alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Jazz Pharmaceuticals stock on TIKR Free→
Looking for New Opportunities?
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
